These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36805545)

  • 1. Effect of flavonoids and CYP3A4 variants on midostaurin metabolism.
    Xu RA; Li QQ; Gao NY; Wang J; Li XY; Ye F; Ni JH; Hu GX; Qian JC
    Food Chem Toxicol; 2023 Apr; 174():113669. PubMed ID: 36805545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone.
    Li Q; Wang J; Wang ZL; Shen Y; Zhou Q; Liu YN; Hu GX; Cai JP; Xu RA
    Biomed Pharmacother; 2023 Dec; 168():115833. PubMed ID: 37935069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
    Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A4 and CYP2C19 genetic polymorphisms and myricetin interaction on tofacitinib metabolism.
    Ye Z; Xia H; Hu J; Liu YN; Wang A; Cai JP; Hu GX; Xu RA
    Biomed Pharmacother; 2024 Jun; 175():116421. PubMed ID: 38719708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline.
    Hu X; Ni J; Gao N; Ye Z; Hu G; Cai J; Qian J
    Chem Biol Interact; 2022 Oct; 366():110123. PubMed ID: 36007633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory Mechanisms of Myricetin on Human and Rat Liver Cytochrome P450 Enzymes.
    Lou D; Bao SS; Li YH; Lin QM; Yang SF; He JY
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):611-618. PubMed ID: 30825074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism.
    Liu YN; Chen J; Wang J; Li Q; Hu GX; Cai JP; Lin G; Xu RA
    Arch Toxicol; 2023 Aug; 97(8):2133-2142. PubMed ID: 37209178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of CYP3A4 genetic polymorphism on crizotinib metabolism and drug-drug interactions.
    Wang J; Xu XY; Li XY; Luo JC; Zhang ZY; Chen J; Cai JP; Zhang LK; Qian JC
    Toxicol Appl Pharmacol; 2024 Aug; 489():117016. PubMed ID: 38925514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of myricetin on cytochrome P450 isoforms CYP1A2, CYP2C9 and CYP3A4 in rats.
    Guo YJ; Zheng SL
    Pharmazie; 2014 Apr; 69(4):306-10. PubMed ID: 24791597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
    Choi SJ; Shin SC; Choi JS
    Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism.
    Ye Z; Hu J; Wang J; Liu YN; Hu GX; Xu RA
    Chem Biol Interact; 2023 Apr; 374():110398. PubMed ID: 36773832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The variability in CYP3A4 activity determines the metabolic kinetic characteristics of ketamine.
    Li M; Li Q; Lin D; Zheng X; Jin L; Cai J; Hu G; Qian J
    Toxicology; 2023 Dec; 500():153682. PubMed ID: 38006927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Polymorphisms and Drug-Drug Interactions Determine the Metabolic Profile of Blonanserin.
    Ye F; Li X; Ni J; Xu X; Luo J; Zhong Y; Wang Y; Wang S; Zhang Y; Hu G; Qian J
    J Pharmacol Exp Ther; 2024 Jan; 388(1):190-200. PubMed ID: 37863485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of myricetin and quercetin on ticagrelor metabolism and the underlying mechanism.
    Wang J; Hu Y; Li Q; Liu YN; Lin J; Xu RA
    Chem Biol Interact; 2024 Apr; 392():110924. PubMed ID: 38401715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib.
    Zhou Q; Ye Z; Xu X; Zhong Y; Luo J; Zhang Z; Chen J; Chen Z; Cai J; Zhang X; Qian J
    Toxicology; 2024 Sep; 507():153903. PubMed ID: 39098371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin.
    Choi DH; Li C; Choi JS
    J Pharm Pharmacol; 2010 Jul; 62(7):908-14. PubMed ID: 20636879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Li C; Lim SC; Kim J; Choi JS
    Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):175-82. PubMed ID: 21442417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
    Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX
    Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
    He H; Tran P; Gu H; Tedesco V; Zhang J; Lin W; Gatlik E; Klein K; Heimbach T
    Drug Metab Dispos; 2017 May; 45(5):540-555. PubMed ID: 28270565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.